Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).

Silvia ScocciantiMarco KrengliLivia MarrazzoStefano Maria MagriniBeatrice DettiVincenzo FuscoLuigi PirtoliDaniela DoinoAlba FiorentinoLaura MasiniDaniela GretoMichela BuglioneGiovanni RubinoFederico LonardiFernanda MigliaccioSalvino MarzanoRiccardo SantoniUmberto RicardiLorenzo Livi

Published in: La Radiologia medica (2017)

This trial confirms that hypofractionated radiotherapy with SIB and association with temozolomide may be a reasonable and feasible option for good prognosis patients with GBM.

Keyphrases

radiation therapy
phase ii study
locally advanced
early stage
radiation induced
open label
rectal cancer
clinical trial
squamous cell carcinoma
newly diagnosed
study protocol
phase iii
white matter
phase ii
multiple sclerosis
small cell lung cancer
brain metastases
cross sectional
double blind